Foundayo cut sleep apnea events by 44% without PAP. Can Lilly turn an obesity pill into its next OSA franchise?
Foundayo cut sleep apnea events by up to 44% in Phase 3 ATTAIN-OSA, giving Eli Lilly another potential obesity-linked OSA treatment.
Pharma & Biotech
Pharma & Biotech
Lilly’s retatrutide cut knee pain as weight fell nearly 29%, but the Phase 3 result raises a bigger osteoarthritis question
Lilly’s retatrutide cut weight by up to 28.7% and significantly reduced knee osteoarthritis pain, but dose and safety trade-offs now matter.
Features & Analysis
Can branded GLP-1 medicines replace compounded weight-loss drugs in Hims & Hers growth strategy?
Lilly is bringing Zepbound and Foundayo to Hims & Hers, turning a former GLP-1 disruptor into a branded obesity-drug distribution channel.
Pharma & Biotech
Eli Lilly brings Zepbound and Foundayo to Hims & Hers, but who gains most from the deal?
Eli Lilly and Hims & Hers expand access to Zepbound and Foundayo from $149 monthly. Discover the impact on obesity medicine distribution.
Pharma & Biotech
Eli Lilly just lifted its 2026 sales outlook by $5.5bn, but can surging GLP-1 demand keep outrunning price pressure?
Eli Lilly raises 2026 revenue guidance to $91bn–$92bn as Mounjaro and Zepbound sales surge. Explore its earnings, pipeline and risks.
Pharma & Biotech
Eli Lilly’s TOGETHER-PsO trial links obesity treatment with psoriasis improvement
Eli Lilly's Taltz and Zepbound show broader immune and metabolic biomarker changes in psoriasis, building on Phase 3b skin clearance results.
Pharma & Biotech
Eli Lilly puts retatrutide, Foundayo and eloraTZP on one stage as obesity pipeline widens
Eli Lilly will use the European Association for the Study of Diabetes 2026 meeting to detail Phase 3 retatrutide results, new Foundayo data and the first Phase 2 readout for eloraTZP, revealing how the company intends to segment an increasingly competitive obesity and diabetes market.
Pharma & Biotech
GLP-1 prescribing rises 310-fold among U.S. children aged 8–11 with obesity
An NYU Langone study of more than 3.5 million children found rapidly increasing off-label GLP-1 prescribing below age 12, concentrated among children with severe obesity and related disease.
Pharma & Biotech
Lilly’s Zepbound plus Taltz sustains stronger psoriasis and psoriatic arthritis outcomes at one year
Eli Lilly and Company says one-year Phase 3b data from TOGETHER-PsO and TOGETHER-PsA show sustained or deeper improvements when Zepbound and Taltz are used together in patients living with psoriatic disease and obesity.
Features & Analysis
Some patients may now receive real retatrutide before FDA approval. Most people discussing it online still will not qualify
Eli Lilly and Company has created a limited expanded-access pathway for adults with severe, treatment-resistant obesity, even as regulators warn that products sold online as retatrutide are unapproved, potentially contaminated and illegal to compound.